{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:23:09Z","timestamp":1791487389213,"version":"4.3.4"},"reference-count":228,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01862","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T14:19:18Z","timestamp":1565360358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":122,"title":["Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Kata P.","family":"Szilveszter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"M\u00f3csai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BOR.0000000000000023","article-title":"Advances in kinase inhibition: treating rheumatic diseases and beyond","volume":"26","author":"Gadina","year":"2014","journal-title":"Curr Opin Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-12-43","article-title":"What is the future of targeted therapy in rheumatology: biologics or small molecules?","volume":"12","author":"Mocsai","year":"2014","journal-title":"BMC Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science."},{"key":"B9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science."},{"key":"B10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/1074-7613(95)90066-7","article-title":"Developmental defects of lymphoid cells in Jak3 kinase-deficient mice","volume":"3","author":"Park","year":"1995","journal-title":"Immunity."},{"key":"B11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity."},{"key":"B12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity."},{"key":"B13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ni910","article-title":"Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock","volume":"4","author":"Karaghiosoff","year":"2003","journal-title":"Nat Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11594","DOI":"10.1073\/pnas.1930781100","article-title":"A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q\/J mice to infection and autoimmunity","volume":"100","author":"Shaw","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.exphem.2013.01.005","article-title":"Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings","volume":"41","author":"Yu","year":"2013","journal-title":"Exp Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/art.37691","article-title":"Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors","volume":"64","author":"Yarilina","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1186\/ar2365","article-title":"Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis","volume":"10","author":"Milici","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.2174\/15680266113139990094","article-title":"Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"13","author":"Gomez-Puerta","year":"2013","journal-title":"Curr Top Med Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J Leukoc Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: rheostats of immune cell signaling","volume":"41","author":"Lowell","year":"2004","journal-title":"Mol Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2005.02.002","article-title":"Src and Syk kinases: key regulators of phagocytic cell activation","volume":"26","author":"Berton","year":"2005","journal-title":"Trends Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12455","article-title":"Tyrosine kinase signaling pathways in neutrophils","volume":"273","author":"Futosi","year":"2016","journal-title":"Immunol Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tcb.2007.09.001","article-title":"Immunoreceptor-like signaling by \u03b22 and \u03b23 integrins","volume":"17","author":"Jakus","year":"2007","journal-title":"Trends Cell Biol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4049\/jimmunol.162.2.1120","article-title":"Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck","volume":"162","author":"Mocsai","year":"1999","journal-title":"J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4049\/jimmunol.1301979","article-title":"B cell-specific loss of Lyn kinase leads to autoimmunity","volume":"192","author":"Lamagna","year":"2014","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.191.4.669","article-title":"Fc\u03b3 receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn","volume":"191","author":"Fitzer-Attas","year":"2000","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.4049\/jimmunol.164.8.4321","article-title":"Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases","volume":"164","author":"Mocsai","year":"2000","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1084\/jem.20132496","article-title":"The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment","volume":"211","author":"Kovacs","year":"2014","journal-title":"J Exp Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","article-title":"Dasatinib","volume":"212","author":"Lindauer","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/BTT.S30182","article-title":"Bosutinib in the management of chronic myelogenous leukemia","volume":"7","author":"Amsberg","year":"2013","journal-title":"Biologics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","article-title":"Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation","volume":"271","author":"Hanke","year":"1996","journal-title":"J Biol Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1021\/cb300172e","article-title":"Development of a highly selective c-Src kinase inhibitor","volume":"7","author":"Brandvold","year":"2012","journal-title":"ACS Chem Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J Med Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"R146","DOI":"10.1186\/ar4329","article-title":"Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy","volume":"15","author":"Liao","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1016\/j.bmcl.2016.10.087","article-title":"Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)","volume":"26","author":"Lam","year":"2016","journal-title":"Bioorg Med Chem Lett."},{"key":"B47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V128.22.624.624","article-title":"Updated results from a phase 1 study of TAK-659, an investigational and reversible SYK inhibitor, in Patients (Pts) with advanced solid tumor or lymphoma malignancies","volume":"128","author":"Kaplan","year":"2016","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1182\/blood-2011-07-369041","article-title":"Dasatinib inhibits proinflammatory functions of mature human neutrophils","volume":"119","author":"Futosi","year":"2012","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/08923973.2015.1028074","article-title":"Therapeutic effects of dasatinib in mouse model of multiple sclerosis","volume":"37","author":"Azizi","year":"2015","journal-title":"Immunopharmacol Immunotoxicol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/bph.13430","article-title":"The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma","volume":"173","author":"da Silva","year":"2016","journal-title":"Br J Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3389\/fimmu.2018.03133","article-title":"Treatment effects of the second-generation tyrosine kinase inhibitor dasatinib on autoimmune arthritis","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/378298a0","article-title":"Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk","volume":"378","author":"Turner","year":"1995","journal-title":"Nature."},{"key":"B53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/378303a0","article-title":"Syk tyrosine kinase required for mouse viability and B-cell development","volume":"378","author":"Cheng","year":"1995","journal-title":"Nature."},{"key":"B54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1126\/science.1079477","article-title":"Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk","volume":"299","author":"Abtahian","year":"2003","journal-title":"Science."},{"key":"B55","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/ni1460","article-title":"Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17","volume":"8","author":"LeibundGut-Landmann","year":"2007","journal-title":"Nat Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1074-7613(02)00303-5","article-title":"Syk is required for integrin signaling in neutrophils","volume":"16","author":"Mocsai","year":"2002","journal-title":"Immunity."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/ni1407","article-title":"Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs","volume":"7","author":"Mocsai","year":"2006","journal-title":"Nat Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J Exp Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/art.27438","article-title":"Genetic deficiency of Syk protects mice from autoantibody-induced arthritis","volume":"62","author":"Jakus","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fimmu.2018.00555","article-title":"Lineage-specific analysis of Syk function in autoantibody-induced arthritis","volume":"9","author":"Nemeth","year":"2018","journal-title":"Front Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.4049\/jimmunol.1100341","article-title":"Deletion of Syk in neutrophils prevents immune complex arthritis","volume":"187","author":"Elliott","year":"2011","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B64","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/jcph.794","article-title":"PRT062607 achieves complete inhibition of the spleen tyrosine kinase at tolerated exposures following oral dosing in healthy volunteers","volume":"57","author":"Coffey","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives Btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell."},{"key":"B68","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/364362a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.4049\/jimmunol.168.6.2695","article-title":"Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice","volume":"168","author":"Middendorp","year":"2002","journal-title":"J Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","article-title":"Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia","volume":"117","author":"Fiedler","year":"2011","journal-title":"Blood."},{"key":"B72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/82_2015_478","article-title":"BTK Signaling in B cell differentiation and autoimmunity","volume":"393","author":"Corneth","year":"2016","journal-title":"Curr Top Microbiol Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/08830185.2012.670334","article-title":"Tec family kinases in inflammation and disease","volume":"31","author":"Horwood","year":"2012","journal-title":"Int Rev Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell."},{"key":"B75","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B77","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/sj.jid.5700459","article-title":"Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis","volume":"126","author":"Sandilands","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol Chem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/jid.2012.239","article-title":"TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice","volume":"133","author":"Leyva-Castillo","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.20041503","article-title":"Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin","volume":"202","author":"Yoo","year":"2005","journal-title":"J Exp Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell."},{"key":"B83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/jid.2008.106","article-title":"Animal models of atopic dermatitis","volume":"129","author":"Jin","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molimm.2011.12.008","article-title":"IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2\/Stat6 signal transduction pathway: implication for atopic dermatitis","volume":"50","author":"Bao","year":"2012","journal-title":"Mol Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cyto.2012.10.031","article-title":"IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis","volume":"61","author":"Bao","year":"2013","journal-title":"Cytokine."},{"key":"B87","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell."},{"key":"B89","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/imj.67_13578","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1172\/JCI200315932","article-title":"Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors","volume":"111","author":"Novak","year":"2003","journal-title":"J Clin Invest."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1172\/JCI82887","article-title":"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda","year":"2016","journal-title":"J Clin Invest."},{"key":"B94","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered Janus-Kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"E3973","DOI":"10.3390\/ijms19123973","article-title":"Topical application of JAK1\/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice","volume":"19","author":"Jin","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol."},{"key":"B100","unstructured":"Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis2018"},{"key":"B101","unstructured":"Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis2018"},{"key":"B102","unstructured":"Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis2017"},{"key":"B103","volume-title":"Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis.","year":"2019"},{"key":"B104","unstructured":"AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis2017"},{"key":"B105","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1002\/cpim.71","article-title":"IL-23- and imiquimod-induced models of experimental psoriasis in mice","volume":"125","author":"Singh","year":"2019","journal-title":"Curr Protoc Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.10.006","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"E1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene."},{"key":"B112","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet."},{"key":"B118","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br J Dermatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI95837","article-title":"\u03b3\u03b4 TCR recruits the Syk\/PI3K axis to drive proinflammatory differentiation program","volume":"128","author":"Muro","year":"2018","journal-title":"J Clin Invest."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1172\/JCI119766","article-title":"Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype","volume":"100","author":"Cook","year":"1997","journal-title":"J Clin Invest."},{"key":"B133","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.0906-6705.2004.00183.x","article-title":"Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis","volume":"13","author":"Cook","year":"2004","journal-title":"Exp Dermatol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0002-9440(10)62322-X","article-title":"Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice","volume":"166","author":"Bhagavathula","year":"2005","journal-title":"Am J Pathol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.4049\/jimmunol.174.8.5047","article-title":"ERK1\/2 regulates epidermal chemokine expression and skin inflammation","volume":"174","author":"Pastore","year":"2005","journal-title":"J Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","article-title":"Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation","volume":"163","author":"Mascia","year":"2003","journal-title":"Am J Pathol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.gastro.2004.05.017","article-title":"The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells","volume":"127","author":"Tanida","year":"2004","journal-title":"Gastroenterology."},{"key":"B139","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer."},{"key":"B140","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaad.2015.03.041","article-title":"Angiogenesis and lymphangiogenesis in inflammatory skin disorders","volume":"73","author":"Varricchi","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2002-12-3793","article-title":"Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis","volume":"102","author":"Xia","year":"2003","journal-title":"Blood."},{"key":"B142","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2353\/ajpath.2008.071074","article-title":"Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor","volume":"173","author":"Halin","year":"2008","journal-title":"Am J Pathol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1182\/blood-2010-10-316356","article-title":"An important role of lymphatic vessel activation in limiting acute inflammation","volume":"117","author":"Huggenberger","year":"2011","journal-title":"Blood."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1084\/jem.20100559","article-title":"Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation","volume":"207","author":"Huggenberger","year":"2010","journal-title":"J Exp Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight."},{"key":"B149","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"e93232","DOI":"10.1371\/journal.pone.0093232","article-title":"Interferon-\u03b3 induces senescence in normal human melanocytes","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1172\/JCI114426","article-title":"Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb\/c mice","volume":"85","author":"Rock","year":"1990","journal-title":"J Clin Invest."},{"key":"B156","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J Immunol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1074\/jbc.M512447200","article-title":"Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies","volume":"281","author":"Calkins","year":"2006","journal-title":"J Biol Chem."},{"key":"B158","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/jid.2008.339","article-title":"Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies","volume":"129","author":"Mao","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fimmu.2018.00136","article-title":"Pemphigus-A disease of desmosome dysfunction caused by multiple mechanisms","volume":"9","author":"Spindler","year":"2018","journal-title":"Front Immunol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"92253","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight."},{"key":"B161","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","article-title":"Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris","volume":"38","author":"Satyam","year":"2009","journal-title":"Immunol Invest."},{"key":"B162","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e1006008","DOI":"10.1371\/journal.pgen.1006008","article-title":"Identification of a functional risk variant for pemphigus vulgaris in the ST18 gene","volume":"12","author":"Vodo","year":"2016","journal-title":"PLoS Genet."},{"key":"B165","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0625.2012.01441.x","article-title":"Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris","volume":"21","author":"Gil","year":"2012","journal-title":"Exp Dermatol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/08916930600971836","article-title":"Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis\u2013possible involvement of the EGF receptor","volume":"39","author":"Frusic-Zlotkin","year":"2006","journal-title":"Autoimmunity."},{"key":"B167","doi-asserted-by":"publisher","first-page":"13804","DOI":"10.1074\/jbc.M611365200","article-title":"Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens","volume":"282","author":"Chernyavsky","year":"2007","journal-title":"J Biol Chem."},{"key":"B168","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/08916930600971885","article-title":"Pemphigus antibody induced phosphorylation of keratinocyte proteins","volume":"39","author":"Rubenstein","year":"2006","journal-title":"Autoimmunity."},{"key":"B169","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2133.2004.06147.x","article-title":"In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades","volume":"151","author":"Sanchez-Carpintero","year":"2004","journal-title":"Br J Dermatol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2019.00626","article-title":"Role of Src and cortactin in pemphigus skin blistering","volume":"10","author":"Kugelmann","year":"2019","journal-title":"Front Immunol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B172","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Bagci","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B173","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/sj.jid.5700254","article-title":"Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients","volume":"126","author":"Woodley","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J Clin Invest."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest."},{"key":"B179","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"J Immunol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.4049\/jimmunol.177.5.3461","article-title":"Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice","volume":"177","author":"Sitaru","year":"2006","journal-title":"J Immunol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.4049\/jimmunol.178.10.6514","article-title":"The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita","volume":"178","author":"Mihai","year":"2007","journal-title":"J Immunol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J Clin Invest."},{"key":"B184","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J Biol Chem."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/eji.201444769","article-title":"Conditional depletion of mast cells has no impact on the severity of experimental epidermolysis bullosa acquisita","volume":"45","author":"Kasprick","year":"2015","journal-title":"Eur J Immunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am J Pathol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fimmu.2019.00200","article-title":"Bullous pemphigoid IgG induces cell dysfunction and enhances the motility of epidermal keratinocytes via Rac1\/proteasome activation","volume":"10","author":"Tie","year":"2019","journal-title":"Front Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.4049\/jimmunol.177.5.3398","article-title":"Role of FcRs in animal model of autoimmune bullous pemphigoid","volume":"177","author":"Zhao","year":"2006","journal-title":"J Immunol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","article-title":"Fc\u03b3 receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid","volume":"184","author":"Schulze","year":"2014","journal-title":"Am J Pathol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0002-9440(10)64182-X","article-title":"Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin","volume":"161","author":"Sitaru","year":"2002","journal-title":"Am J Pathol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/blood-2005-08-3123","article-title":"Differential roles for beta2 integrins in experimental autoimmune bullous pemphigoid","volume":"107","author":"Liu","year":"2006","journal-title":"Blood."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/exd.13434","article-title":"CD11b-deficient mice exhibit an increased severity in the late phase of antibody transfer-induced experimental epidermolysis bullosa acquisita","volume":"26","author":"Deng","year":"2017","journal-title":"Exp Dermatol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The Syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"Nemeth","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J Pathol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals sYK as a key regulator of inflammation in experimental epidermolysis Bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"11004","DOI":"10.1038\/ncomms11004","article-title":"Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo","volume":"7","author":"Nemeth","year":"2016","journal-title":"Nat Commun."},{"key":"B203","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF02507102","article-title":"Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid","volume":"288","author":"Schmidt","year":"1996","journal-title":"Arch Dermatol Res."},{"key":"B204","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0923-1811(95)00435-1","article-title":"Detection of IL-1 alpha, IL-1 beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid","volume":"11","author":"Schmidt","year":"1996","journal-title":"J Dermatol Sci."},{"key":"B205","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0190-9622(96)80146-0","article-title":"Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects","volume":"3","author":"Schmidt","year":"1996","journal-title":"J Am Acad Dermatol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm."},{"key":"B207","first-page":"S16","article-title":"Therapeutic efficacy of a novel selective JAK2 inhibitor (CEP-33779) in organ-specific, autoantibody-induced tissue injury","volume":"134","author":"Samavedam","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/art.27452","article-title":"Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice","volume":"62","author":"Deng","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B210","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-017-1500-0","article-title":"Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus","volume":"20","author":"Chalmers","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaut.2013.01.007","article-title":"Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review","volume":"41","author":"Yu","year":"2013","journal-title":"J Autoimmun."},{"key":"B212","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrrheum.2015.106","article-title":"Pathogenesis and targeted treatment of skin injury in SLE","volume":"11","author":"Deng","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.cyto.2015.01.031","article-title":"The role of cytokines in the pathogenesis of cutaneous lupus erythematosus","volume":"73","author":"Robinson","year":"2015","journal-title":"Cytokine."},{"key":"B214","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B215","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11926-018-0713-9","article-title":"Pathogenesis of skin injury of systemic lupus erythematosus","volume":"20","author":"Deng","year":"2018","journal-title":"Curr Rheumatol Rep."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet."},{"key":"B218","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/bjd.15105","article-title":"Are neutrophilic dermatoses autoinflammatory disorders?","volume":"178","author":"Satoh","year":"2018","journal-title":"Br J Dermatol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of inflammation in neutrophil-mediated skin diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front Immunol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2017.03.014","article-title":"Tyrosine kinase SYK licenses MyD88 adaptor protein to instigate IL-1\u03b1-mediated inflammatory disease","volume":"46","author":"Gurung","year":"2017","journal-title":"Immunity."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.4049\/jimmunol.1800760","article-title":"Cutting edge: dysregulated CARD9 signaling in neutrophils drives inflammation in a mouse model of neutrophilic dermatoses","volume":"201","author":"Tartey","year":"2018","journal-title":"J Immunol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/archderm.140.5.570","article-title":"Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction","volume":"140","author":"Kawakami","year":"2004","journal-title":"Arch Dermatol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2230.2005.01996.x","article-title":"Cutaneous manifestations of granulocyte colony-stimulating factor","volume":"31","author":"White","year":"2006","journal-title":"Clin Exp Dermatol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol Online J."},{"key":"B225","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr Opin Chem Biol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjd.17149","article-title":"Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials","volume":"180","author":"Strober","year":"2019","journal-title":"Br J Dermatol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T23:50:01Z","timestamp":1695081001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":228,"alternative-id":["10.3389\/fimmu.2019.01862"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01862","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"article-number":"1862"}}